Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in "special populations".

Stanislas PolLucia Parlati

Published in: Liver international : official journal of the International Association for the Study of the Liver (2019)

The notion of "special populations" is no longer pertinent with pangenotypic DAAs combinations. International guidelines recommend treating all infected patients and the next challenge is not the therapeutic choice, but to improve the limitations for screening and access to care in HCV infection.

Keyphrases

healthcare
hepatitis c virus
palliative care
genetic diversity
quality improvement
clinical practice
pain management
human immunodeficiency virus
decision making
affordable care act
replacement therapy
smoking cessation